Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenacapavir - Gilead Sciences

Next Previous
Drug Profile

Lenacapavir - Gilead Sciences

Alternative Names: GS 6207; GS-6207-02; GS-714207; GS-HIV; GS-HIV Na; Lenacapavir sodium; Sunlenca; Yeytuo; Yeztugo

Latest Information Update: 05 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Class Acetamides; Alkynes; Antiretrovirals; Antivirals; Chlorobenzenes; Fluorinated hydrocarbons; Pyrazoles; Pyridines; Sulfonamides; Sulfones
  • Mechanism of Action Capsid protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 25 Feb 2026 Efficacy and adverse events data from the phase III ARTISTRY-2 and phase II/III ARTISTRY-1 trial in HIV-1 infections released by Gilead Sciences
  • 20 Feb 2026 Launched for HIV-1 infections (Combination therapy, In adolescents, In the elderly, Treatment-experienced, In adults) in USA (PO)
  • 20 Feb 2026 Launched for HIV-1 infections (Combination therapy, In the elderly, Treatment-experienced, In adults) in Australia (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top